Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jerry S Wolinsky

Showing results (51-60 of 139) with videos related to

Pageof 14
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 6, 2011
Intracortical lesions by 3T magnetic resonance imaging and correlation with cognitive impairment in multiple sclerosisFlavia Nelson, Sushmita Datta, Nereyda Garcia, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 30, 2016
Baseline EDSS proportions in MS clinical trials affect the overall outcome and power: A cautionary noteGuoqiao Wang, Gary R Cutter, Stacey S Cofield, et al.
Radiology|January 16, 2008
Diffusion-tensor MR imaging of cortical lesions in multiple sclerosis: initial findingsAziz H Poonawalla, Khader M Hasan, Rakesh K Gupta, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|November 18, 2011
Multimodal quantitative magnetic resonance imaging of thalamic development and aging across the human lifespan: implications to neurodegeneration in multiple sclerosisKhader M Hasan, Indika S Walimuni, Humaira Abid, et al.
Multiple Sclerosis and Related Disorders|July 22, 2015
GLACIER: An open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40 mg three-times weekly versus 20 mg daily in patients with relapsing-remitting multiple sclerosisJerry S Wolinsky, T Erik Borresen, Dennis W Dietrich, et al.
European Journal of Neurology|December 20, 2021
Early first-line treatment response and subsequent disability worsening in relapsing-remitting multiple sclerosisMarcus W Koch, Jop Mostert, Pavle Repovic, et al.
Magnetic Resonance in Medicine|January 16, 2018
Interleaved susceptibility-weighted and FLAIR MRI for imaging lesion-penetrating veins in multiple sclerosisRefaat E Gabr, Amol S Pednekar, Arash Kamali, et al.
Multiple Sclerosis and Related Disorders|March 20, 2015
Regional gray matter atrophy in relapsing remitting multiple sclerosis: baseline analysis of multi-center dataSushmita Datta, Terrell D Staewen, Stacy S Cofield, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 20, 2018
Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesionsColm Elliott, Jerry S Wolinsky, Stephen L Hauser, et al.
Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging|August 20, 2016
Limbic Pathway Correlates of Cognitive Impairment in Multiple SclerosisZafer Keser, Khader M Hasan, Benson Mwangi, et al.
Pageof 14

Showing results (51-60 of 139) with videos related to

Sort By:
Pageof 14
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 6, 2011
Intracortical lesions by 3T magnetic resonance imaging and correlation with cognitive impairment in multiple sclerosisFlavia Nelson, Sushmita Datta, Nereyda Garcia, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 30, 2016
Baseline EDSS proportions in MS clinical trials affect the overall outcome and power: A cautionary noteGuoqiao Wang, Gary R Cutter, Stacey S Cofield, et al.
Radiology|January 16, 2008
Diffusion-tensor MR imaging of cortical lesions in multiple sclerosis: initial findingsAziz H Poonawalla, Khader M Hasan, Rakesh K Gupta, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|November 18, 2011
Multimodal quantitative magnetic resonance imaging of thalamic development and aging across the human lifespan: implications to neurodegeneration in multiple sclerosisKhader M Hasan, Indika S Walimuni, Humaira Abid, et al.
Multiple Sclerosis and Related Disorders|July 22, 2015
GLACIER: An open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40 mg three-times weekly versus 20 mg daily in patients with relapsing-remitting multiple sclerosisJerry S Wolinsky, T Erik Borresen, Dennis W Dietrich, et al.
European Journal of Neurology|December 20, 2021
Early first-line treatment response and subsequent disability worsening in relapsing-remitting multiple sclerosisMarcus W Koch, Jop Mostert, Pavle Repovic, et al.
Magnetic Resonance in Medicine|January 16, 2018
Interleaved susceptibility-weighted and FLAIR MRI for imaging lesion-penetrating veins in multiple sclerosisRefaat E Gabr, Amol S Pednekar, Arash Kamali, et al.
Multiple Sclerosis and Related Disorders|March 20, 2015
Regional gray matter atrophy in relapsing remitting multiple sclerosis: baseline analysis of multi-center dataSushmita Datta, Terrell D Staewen, Stacy S Cofield, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 20, 2018
Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesionsColm Elliott, Jerry S Wolinsky, Stephen L Hauser, et al.
Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging|August 20, 2016
Limbic Pathway Correlates of Cognitive Impairment in Multiple SclerosisZafer Keser, Khader M Hasan, Benson Mwangi, et al.
Pageof 14